The FDA ( Food and Drug Administration ) has informed patients and health care professionals that the sponsor of Zelnorm ( Tegaserod ), Novartis Pharmaceuticals, has agreed to stop selling Zelnorm.
Zelnorm is being taken off the market because a new safety analysis has found a higher chance of myocardial infarction, stroke, and worsening heart chest pain that can become a myocardial infarction in patients treated with Zelnorm compared to those treated with placebo.
Author:
Time:
Monday, May 7th, 2007 at 10:08 pm
Category:
Comments:
You can leave a response, or trackback from your own site.
RSS:
You can follow any responses to this entry through the RSS 2.0 feed.
Navigation: